Johnson & Johnson Oklahoma Opioid Trial Verdict Announced – $572 Million Loss for J&J/Janssen

Johnson & Johnson conducted a misleading marketing campaign for their anti-psychotic drug, Risperdal. Approved by the U.S. Food and Drug Administration (FDA) to treat adults with schizophrenia, Johnson & Johnson marketed the drug for use in children.

Johnson & Johnson Oklahoma Opioid Trial Verdict Announced – $572 Million Loss for J&J/Janssen

By Mark A. York, Mass Tort Nexus Media 

(MASS TORT NEXUS MEDIA) The first court verdict to come out of the massive …